As part of your daily routine as an active trader or investor, it's important to track the stocks in the market that are making the biggest percentage gains and the biggest percentage losses.

Stocks that are making large moves to the upside are favorites among short-term traders who want to capture some of that massive volatility. Stocks that are making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Stocks that are in favor and making large moves is a segment of the market that I tweet about on a regular basis.These are also the exact type of stocks that I love to trade and alert to my subscribers in real-time.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

aTyr Pharma

  • Wednesday's Range: $3.06-$3.25
  • 52-Week Range: $2.48-$19.46
  • Wednesday's Volume: 262,000
  • Three-Month Average Volume: 236,227

aTyr Pharma (LIFE) - Get Report , a biotherapeutics company, engages in the discovery and clinical development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. This stock closed up 5.8% to $3.24 in Wednesday's trading session.

From a technical perspective, aTyr Pharma spiked sharply higher on Wednesday right off its 50-day moving average of $3.05 a share and back above its 20-day moving average of $3.10 a share with above-average volume. This high-volume jump to the upside also managed to push shares of aTyr Pharma into breakout territory, since it cleared and closed above some near-term overhead resistance at $3.19 a share. Market players should now look for a continuation move to the upside in the short-term if this stock manages to take out Wednesday's intraday high of $3.25 a share with strong volume.

Traders should now look for long-biased trades in aTyr Pharma as long as it's trending above its 50-day moving average of $3.05 a share or above more near-term support levels at $2.96 to $2.88 a share and then once it sustains a move or close above Wednesday's intraday high of $3.25 a share with volume that registers near or above 236,227 shares. If that move gets underway soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $3.42 to $3.60, or even $3.85 to $4 a share.

Neos Therapeutics

  • Wednesday's Range: $7.50-$7.88
  • 52-Week Range: $6.33-$23.00
  • Wednesday's Volume: 147,000
  • Three-Month Average Volume: 131,791

Neos Therapeutics (NEOS) - Get Report , a pharmaceutical company, engages in the development, manufacture and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies. This stock closed up 3.7% to $7.75 in Wednesday's trading session.

From a technical perspective, Neos Therapeutics spiked notably higher on Wednesday right above some near-term support at $7.32 a share with above-average volume. This stock has been uptrending a bit over the last few weeks, with shares moving higher off its low of $6.33 a share to its recent high of $7.89 a share. During that uptrend, shares of Neos Therapeutics have been making mostly higher lows and higher highs, which is bullish technical price action. This bump to the upside on Wednesday has now pushed this stock within range of triggering a near-term breakout trade. That trade will trigger if this stock manage to take out some near-term overhead resistance levels at $7.89 a share to its 50-day moving average of $8.05 a share and then above more near-term resistance at $8.25 a share with high volume.

Traders should now look for long-biased trades in Neos Therapeutics as long as it's trending above some near-term support levels at $7.32 a share or above its 20-day moving average of $7.12 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 131,791 shares. If that breakout hits soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $9 to $9.25, or even $9.65 to $10 a share.

Synergy Pharmaceuticals

  • Wednesday's Range: $4.96-$5.32
  • 52-Week Range: $2.50-$7.72
  • Wednesday's Volume: 5.47 million
  • Three-Month Average Volume: 2.80 million

Synergy Pharmaceuticals (SGYP) - Get Report , a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal disorders and diseases. This stock closed up 8.8% to $5.30 in Wednesday's trading session.

From a technical perspective, Synergy Pharmaceuticals ripped sharply higher on Wednesday right off its 20-day moving average of $4.93 a share with strong upside volume flows. This stock has been uptrending extremely strong over the last six months, with shares ripping higher off its 52-week low of $2.50 a share to its recent high of $5.38 a share. During that uptrend, shares of Synergy Pharmaceuticals have been making mostly higher lows and higher highs, which is bullish technical price action. This rip higher on Wednesday is now quickly pushing this stock within range of triggering a near-term breakout trade. That trade will trigger if this stock manage to take out some near-term overhead resistance at $5.38 a share with high volume.

Traders should now look for long-biased trades in Synergy Pharmaceuticals as long as it's trending above its 20-day moving average of $4.93 a share or above more near-term support at $4.72 a share and then once it sustains a move or close above $5.38 a share with volume that hits near or above 2.80 million shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $6 to $6.25, or even $6.50 to $7 a share.

TransEnterix

  • Wednesday's Range: $1.45-$1.58
  • 52-Week Range: $1.03-$6.10
  • Wednesday's Volume: 736,000
  • Three-Month Average Volume: 818,417

TransEnterix (TRXC) - Get Report , a medical device company, focuses on the development and commercialization of surgical robotic systems. This stock closed up 6.1% to $1.55 in Wednesday's trading session.

From a technical perspective, TransEnterix spiked sharply higher on Wednesday right off its 20-day moving average of $1.44 a share with decent upside volume flows. This stock recently formed a double bottom chart pattern, after shares found some buying interest at $1.33 to $1.35 a share over the last two months. Following that potential bottom, shares of TransEnterix have now started to trend higher and it's quickly moving within range of triggering a big breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $1.59 to $1.63 a share with high volume.

Traders should now look for long-biased trades in TransEnterix as long as it's trending above those recent double bottom support levels and then once it sustains a move or close above those breakout levels with volume that hits near or above 818,417 shares. If that breakout develops soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $1.97 to $2, or even $2.31 to its 200-day moving average of $2.41 a share.

Cascadian Therapeutics

  • Wednesday's Range: $1.11-$1.21
  • 52-Week Range: $0.82-$3.89
  • Wednesday's Volume: 1.42 million
  • Three-Month Average Volume: 754,609

Cascadian Therapeutics (CASC) , a clinical-stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of cancer. This stock closed up 8.1% to $1.20 in Wednesday's trading session.

From a technical perspective, Cascadian Therapeutics ripped sharply higher on Wednesday right off its 50-day moving average of $1.12 a share and back above its 20-day moving average of $1.15 a share with strong upside volume flows. This high-volume spike to the upside is now quickly pushing shares of Cascadian Therapeutics within range of triggering a near-term breakout trade. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $1.21 to $1.23 a share with high volume.

Traders should now look for long-biased trades in Cascadian Therapeutics as long as it's trending above its 50-day moving average of $1.12 a share or above more key near-term support levels at $1.10 to $1.05 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 754,609 shares. If that breakout kicks off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $1.31 to its 200-day moving average of $1.35 a share, or even $1.43 to $1.53 a share.

Inotek Pharmaceuticals

  • Wednesday's Range: $7.03-$8.25
  • 52-Week Range: $5.81-$15.49
  • Wednesday's Volume: 1.76 million
  • Three-Month Average Volume: 255,372

Inotek Pharmaceuticals (ITEK) , a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye in the U.S. This stock closed up 12.6% to $8.02 in Wednesday's trading session.

From a technical perspective, Inotek Pharmaceuticals exploded sharply higher on Wednesday right off its 20-day moving average of $7.08 a share and back above its 50-day moving average of $7.62 a share with monster upside volume flows. This high-volume rip to the upside also managed to push this stock into breakout territory, after it closed above some key near-term overhead resistance levels at$7.40 to its 50-day moving average. This move is now quickly pushing shares of Inotek Pharmaceuticals within range of triggering another breakout trade. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $8.25 to its 200-day moving average of $8.38 a share with high volume.

Traders should now look for long-biased trades in Inotek Pharmaceuticals as long as it's trending above its 50-day moving average of $7.62 a share or above its previous breakout levels at $7.41 to around $7.25 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 255,372 shares. If that breakout takes hold soon, then this stock will set up to re-fill some more of its previous gap-down-day zone from August that started near $9.50 a share.

Synthetic Biologics

  • Wednesday's Range: $1.59-$1.69
  • 52-Week Range: $0.93-$3.44
  • Wednesday's Volume: 519,000
  • Three-Month Average Volume: 505,298

Synthetic Biologics (SYN) - Get Report , a clinical stage company, engages in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases in the U.S. This stock closed up 7% to $1.68 in Wednesday's trading session.

From a technical perspective, Synthetic Biologics ripped sharply higher on Wednesday back above its 20-day moving average of $1.64 a share with decent upside volume flows. This above-average volume spike to the upside is now quickly pushing shares of Synthetic Biologics within range of triggering a major breakout trade above some key near-term overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at its 50-day moving average of $1.70 a share and then above more key resistance levels at $1.75 to $1.81 a share with high volume.

Traders should now look for long-biased trades in Synthetic Biologics as long as it's trending above some key near-term support levels at $1.58 to $1.52 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 505,298 shares. If that breakout materializes soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $1.94 to $2.10, or even $2.25 to $2.40 a share.

This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.